Mostrar el registro sencillo del ítem
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
dc.contributor.author | M., Majem | |
dc.contributor.author | O., Juan | |
dc.contributor.author | A., Insa | |
dc.contributor.author | N., Reguart | |
dc.contributor.author | J.M., Trigo | |
dc.contributor.author | E., Carcereny | |
dc.contributor.author | García Campelo, María del Rosario | |
dc.contributor.author | Y., Garcia | |
dc.contributor.author | M., Guirado | |
dc.contributor.author | M., Provencio | |
dc.date.accessioned | 2022-02-01T12:59:52Z | |
dc.date.available | 2022-02-01T12:59:52Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1699-048X | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/30446985 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16054 | |
dc.description.abstract | Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value. | en |
dc.language.iso | eng | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Immunotherapy | * |
dc.subject.mesh | Clinical Trials as Topic | * |
dc.subject.mesh | Lung Neoplasms | * |
dc.subject.mesh | Carcinoma | * |
dc.subject.mesh | Radiotherapy | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Combined Modality Therapy | * |
dc.subject.mesh | Practice Guidelines as Topic | * |
dc.subject.mesh | Prognosis | * |
dc.title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) | en |
dc.type | Artigo | es |
dc.identifier.doi | 10.1007/s12094-018-1978-1 | |
dc.identifier.pmid | 30446985 | |
dc.identifier.sophos | 34017 | |
dc.issue.number | 1 | es |
dc.journal.title | Clinical & Translational Oncology | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médica | es |
dc.page.initial | Wed Mar 01 00:00:00 CET 2017 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.decs | carcinoma | * |
dc.subject.decs | pronóstico | * |
dc.subject.decs | tratamiento combinado | * |
dc.subject.decs | inmunoterapia | * |
dc.subject.decs | ensayos clínicos como asunto | * |
dc.subject.decs | radioterapia | * |
dc.subject.decs | humanos | * |
dc.subject.decs | guías de práctica clínica como asunto | * |
dc.subject.decs | neoplasias pulmonares | * |
dc.subject.keyword | CHUAC | es |
dc.typefides | Guías Clínicas | es |
dc.typesophos | Guías Clínicas | es |
dc.volume.number | 21 | es |